Penicillin G prices remain elevated
Management noted that Penicillin G and Cefoperazone prices are still tough, which could pressure gross margins if sustained.
medium · management_commentary
Alkem Laboratories Limited — Q1 FY24
Alkem Laboratories reported Q1 FY2024 revenue growth of 15.2% YoY, driven by strong international business crossing INR 1,000 crore for the first time.
neutral
medium
✓ Verified against BSE filing
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
India growth may miss double-digit target
Management revised India growth to high single digits, citing Q1 slowdown and no significant uptick in Q2 so far. Analyst questioned if acute season could lift growth, but management remained cautious.
medium · analyst_questionTrade generics competition from large pharma entrants
Analyst raised concern about big pharma entering trade generics. Management acknowledged potential long-term structural impact but cited brand loyalty and stockist relationships as moats.
low · analyst_questionEnzene break-even delayed beyond next year
Enzene is expected to remain loss-making in FY2024, with break-even targeted next year. CDMO business is lumpy, and management expressed uncertainty about timing.
medium · management_commentary